Zoetis trades at 12x earnings with 3% yield amid challenges, seen as a buy for value and dividend investors.

Zoetis (ZTS), a global leader in animal health products, now trades at a forward price-to-earnings ratio of 12 and offers a nearly 3% dividend yield after a prolonged price decline. Despite facing competition, weaker U.S. companion animal sales, and lowered guidance, Zoetis maintains strong profitability and market dominance. The company is actively repurchasing shares and sustaining strong capital returns with a healthy balance sheet, even with $9 billion in long-term debt. This makes Zoetis an attractive buy for investors focused on value and dividends who can tolerate short-term volatility and competitive pressures.